查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1190650

藥物洗脫球囊市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Drug Eluting Balloon Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，藥物洗脫球囊市場預計將以 18% 左右的複合年增長率增長。

COVID-19 對市場的增長產生了重大影響。 由於高感染率和隔離限制，COVID-19 大流行對外科手術產生了不利影響。 由於醫院和診斷中心的入院人數減少，心血管疾病患者的診斷和治療延誤也影響了市場。 這種診斷和治療的延誤導致對藥物洗脫球囊的需求略有下降，影響了市場增長。 例如，2022 年 3 月在 NCBI 發表的一項研究發現，成人心臟手術量減少了 52.7%，選擇性病例減少了 65.5%，表明 COVID-19 對心臟手術的負面影響。 然而，2021 年 4 月發表的另一項 NCBI 研究稱，COVID-19 可以通過 ACE2 增加動脈粥樣硬化的發展，ACE2 也是 SARS-CoV-2 病毒的受體。 因此，COVID-19 對人體的長期影響可能會增加動脈硬化等心髒病的患病率，從而增加對藥物洗脫球囊的需求，並為市場增長做出貢獻。期待您的貢獻。

此外，全球冠狀動脈疾病和外周動脈疾病發病率的增加也有望推動市場增長。 政府和私人組織加大研發力度，以及為提高人們對心髒病的認識所做的不懈努力，也在推動市場的增長。

根據澳大利亞健康與福利研究所的數據，到 2022 年 5 月，在 1180 萬住院患者中，7.0% 在重症監護室，3.8% 因心血管疾病住院。 根據美國心臟協會 2021 年報告，外周動脈疾病 (PAD) 影響全球 2 億多人，並與高死亡率和發病率相關。 此外，易患心血管疾病的老齡化人口增加和醫療成本上升預計將推動市場增長。 例如，愛思唯爾 (Elsevier) 於 2021 年 12 月發布的調查結果顯示，在 45 歲及以上的人群中，自我報告的已確診心血管疾病 (CVD) 的總體患病率為 29.4%。 隨著年齡的增長，患病率從 45-54 歲的 22% 增加到 70 歲及以上的 38%，這表明老年人患心血管疾病的風險增加。 這些心血管疾病的流行預計將推動對藥物洗脫球囊的需求，因為藥物洗脫球囊用於治療多種心血管疾病，從而幫助患病患者康復。

然而，藥物洗脫球囊的開發和商業化成本高昂，加上嚴格的監管程序，阻礙了市場增長。

藥物洗脫球囊市場趨勢

周邊藥物洗脫球囊有望在預測期內實現健康成長

藥物洗脫球囊在外周動脈疾病的治療中發揮著重要作用。 外周動脈疾病患病率上升和老年人口增加預計將推動該領域的增長。

根據美國心臟協會 2021 年報告，外周動脈疾病 (PAD) 影響著全世界 2 億多人，並且與高死亡率和發病率有關。 隨著世界人口老齡化，PAD 可能變得越來越普遍。 統計數據顯示，PAD 正在以更快的速度增長，這最終推動了外周藥物洗脫球囊的細分市場。 根據美國心臟協會 2021 年 8 月發表的另一項科學研究，下肢 PAD 影響全球超過 2.3 億人，並與冠心病和中風等多種不良臨床結果相關。 ， ETC。）。 由於 PAD 發病率的增加，預計在預測期內外周藥物洗脫球囊的使用將會增加。

由於藥物洗脫球囊在外周動脈疾病治療中的使用增加、擴大適應症的研發增加以及上市，預計外周藥物洗脫球囊部分將佔據很大份額外周動脈部分的新產品。

預期的產品發布以及創新塗層和氣球技術的開發預計將在預測期內推動該細分市場的增長。

預計在預測期內北美將佔據很大的市場份額

在北美，久坐不動的生活方式加上缺乏運動、飲食不當、焦慮和壓力導致糖尿病和肥胖等慢性病以及冠狀動脈疾病、中風和心房顫動等多種心血管疾病。很大程度上是由於患病率上升

Cedars Sinai 於 2022 年 1 月更新的數據顯示，冠狀動脈旁路移植手術 (CABG)，也稱為冠狀動脈搭橋或搭橋手術，是最常見的心臟手術類型。 在美國，每年有超過 300,000 人成功地進行搭橋手術。 此類與心血管疾病相關的各種外科手術的負擔預計將推動對藥物洗脫球囊的需求，為該地區的市場增長創造有利可圖的機會。

此外，根據美國疾病控制與預防中心 (CDC) 於 2022 年 7 月更新的數據，冠心病是美國 20 歲及以上成年人中最常見的心髒病類型。約有 2010 萬人已被證明患有這種疾病。 根據CDC數據，每40秒就有一人心髒病發作，美國每年有近80.5萬人心髒病發作。 由於心血管疾病的高負擔，需要使用藥物洗脫球囊。

特別是北美新興國家，心髒病患者多，醫療費用增加，市場有望增長。

藥物洗脫球囊市場競爭分析

藥物洗脫球囊市場整合度適中，競爭激烈。 公司正專注於氣球技術的創新和擴大產品適應症以增加市場份額。 市場上的主要市場參與者包括 Medtronic PLC、Boston Scientific Corporation、Becton、Dickson and Company、Terumo Corporation、Koninklijke Philips NV 等。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 外周動脈疾病和冠狀動脈疾病的患病率增加
    • 導致心血管疾病的老年人口增加
  • 市場製約因素
    • 藥物洗脫球囊的開發和商業化成本高昂
    • 副作用和產品召回
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按產品分類
    • 用於冠狀動脈的藥物洗脫球囊
    • 外周藥物洗脫球囊
    • 其他產品（腎臟/泌尿科）
  • 按技術
    • 免費包
    • 反包
    • Endura 外套
    • 其他技術
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Medtronic PLC
    • Boston Scientific Corporation
    • Becton, Dickson and Company
    • Terumo Corporation
    • Koninklijke Philips NV
    • Cook Group Incorporated
    • Biotronik
    • B. Braun Melsungen AG
    • SurModics Inc.

第7章 市場機會今後動向

簡介目錄
Product Code: 67876

The drug-eluting balloon market is expected to register an approximate CAGR of 18% during the forecast period.

COVID-19 had a significant impact on the growth of the market. The COVID-19 pandemic has negatively affected surgical procedures due to the high rate of infection and lockdown restrictions. A delay in diagnosis and treatments was also observed in patients with cardiovascular diseases as a result of a reduction of footfall in hospitals and diagnostic centers, which impacted the market studied as well. Such delay in diagnosis and treatment led to a slight decrease in the demand for drug-eluting balloons, thereby affecting the growth of the market. For instance, according to a research study published in NCBI in March 2022, there was a 52.7% reduction in the volume of adult cardiac surgeries and a 65.5% reduction in elective cases, which indicated the negative impact of COVID-19 on cardiac surgical procedures. However, another NCBI research study published in April 2021 stated that COVID-19 could increase the development of atherosclerosis due to ACE2, which is also a receptor for the SARS-CoV-2 virus. Thus, the long-term effect of COVID-19 on the human body may increase the prevalence of atherosclerosis and other cardiac diseases, which is expected to increase the demand for drug-eluting balloons, thereby by contributing to the growth of the market.

The increasing incidence of coronary and peripheral artery diseases around the world is expected to boost the market's growth. In addition, increasing research and development supported by government and private institutions and continuous initiatives about awareness regarding heart diseases are fuelling the market growth.

According to the Australian Institute of Health and Welfare, in May 2022, out of 11.8 million admissions, 7.0% of hospitalizations involved a stay in the intensive care unit, and 3.8% of hospitalizations involved cardiovascular diseases. According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. Moreover, the increasing geriatric population, which is prone to cardiovascular diseases, and growing healthcare spending are projected to bolster market growth. For instance, according to the research study published in December 2021, by Elsevier, for older people aged 45 and above, the overall self-reported prevalence of diagnosed cardiovascular diseases (CVDs) was 29.4%. The prevalence rate increased with age, from 22% in the 45-54 age group to 38% in the 70+ age group, showing that the senior population is at high risk of having CVDs. Such prevalence of various cardiovascular conditions is expected to drive the demand for drug-eluting balloons as they are used to treat various cardiovascular conditions, thereby helping in the recovery of affected patients.

However, the high cost of development and commercialization of drug-eluting balloons, coupled with stringent regulatory procedures, are hampering the market growth.

Drug Eluting Balloon Market Trends

Peripheral Drug-eluting Balloons are Expected to Grow at a Healthy Rate Over the Forecast Period

Drug-eluting balloons play an important role in the treatment of peripheral artery diseases. The growing prevalence of peripheral artery diseases, coupled with the increasing geriatric population, is expected to boost segment growth.

According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. With the aging global population, PAD may likely become increasingly common. Statistics show that PADs are increasing at a faster pace, which is ultimately driving the segment for peripheral drug-eluting balloons. Another scientific study published by the American Heart Association in August 2021 stated that lower extremity PAD affects more than 230 million people worldwide and is linked to an elevated risk of several unfavorable clinical outcomes (including cardiovascular diseases like coronary heart disease and stroke and limb outcomes, like amputee status). The increased incidence of PAD is expected to boost the use of peripheral drug-eluting balloons over the forecast period.

The segment for peripheral drug-eluting balloons is expected to have a significant share owing to the increased usage of drug-eluting balloons in the treatment of peripheral artery diseases and growing R&D in expanding the indications, and new product launches in the peripheral artery segment.

The anticipated product launches, coupled with the development of innovative coating and balloon technologies, are expected to boost the segment's growth over the forecast period.

North America is Expected to Have Significant Market Share Over the Forecast Period

The major factors attributing to the growth are a sedentary lifestyle lacking physical activity, lack of proper diet, anxiety, and stress resulting in chronic diseases, such as diabetes and obesity, leading to an increase in the prevalence of multiple cardiovascular diseases like coronary artery disease, strokes, and atrial fibrillation.

The data updated by Cedars-Sinai in January 2022 showed that coronary artery bypass graft surgery (CABG), also known as coronary artery bypass, or bypass surgery, is the most common type of heart surgery. More than 300,000 people have successful bypass surgeries in United States each year. Such a burden of various cardiovascular disease-related surgical procedures is expected to drive the demand for drug-eluting balloons and provide lucrative opportunities for the growth of the market in this region.

In addition, the Centers for Disease Control and Prevention (CDC) data updated in July 2022 showed that coronary heart disease is the most common type of heart disease, and approximately 20.1 million adults of age 20 and older had the disease in United States. Per the CDC data, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in United States have a heart attack every year. Thus, the high burden of cardiovascular diseases demands the availability of drug-eluting balloons.

The presence of a large pool of people with heart diseases and growing healthcare spending, especially in emerging countries of North America, are expected to boost the market growth.

Drug Eluting Balloon Market Competitive Analysis

The drug-eluting balloon market is moderately consolidated and competitive. Companies are focusing on innovating balloon technologies and expanding product indications to increase their market share. The key market players operating in the market include Medtronic PLC, Boston Scientific Corporation, Becton, Dickson and Company, Terumo Corporation, and Koninklijke Philips NV, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Peripheral and Coronary Artery Diseases
    • 4.2.2 Rising Geriatric Population Leading to Cardiovascular Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Development and Commercialization of Drug-eluting Balloons
    • 4.3.2 Adverse Effects and Product Recalls
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Coronary Drug-eluting Balloon
    • 5.1.2 Peripheral Drug-eluting Balloon
    • 5.1.3 Other Products (Renal/Urology)
  • 5.2 By Technology
    • 5.2.1 FreePac
    • 5.2.2 TransPac
    • 5.2.3 EnduraCoat
    • 5.2.4 Other Technologies
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Medtronic PLC
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 Becton, Dickson and Company
    • 6.1.4 Terumo Corporation
    • 6.1.5 Koninklijke Philips NV
    • 6.1.6 Cook Group Incorporated
    • 6.1.7 Biotronik
    • 6.1.8 B. Braun Melsungen AG
    • 6.1.9 SurModics Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS